Compare MPLX LP (MPLX) vs Merck & Co., Inc. (MRK) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
MPLX LP vs Merck & Co., Inc. — how do they compare? MPLX LP trades at $56.64 (market cap $57.97B), while Merck & Co., Inc. trades at $126.26 (market cap $307.25B). The key difference: Merck & Co., Inc. is far larger — about 5.3× MPLX LP's market cap, and MPLX LP pays the higher dividend (7.54%). Which is the better fit depends on your goals.
| MPLX | MRK | |
|---|---|---|
Market Cap | $57.97B | $307.25B |
Sector | Technology | Health |
52-Week High | $59.17 | $129.52 |
52-Week Low | $47.80 | $77.60 |
Enterprise Value | $82.60B | $350.66B |
Dividend Yield | 7.54% | 2.73% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
MPLX trades at $57.13, showing modest daily gains of 0.12%. The stock maintains a bullish technical outlook with strong moving average signals, while fundamentals reveal robust profitability with 41.24% net margins and consistent earnings beats in recent quarters. Recent news highlights the company's resilient midstream business model and attractive dividend yield, with analyst consensus strongly favoring the stock.
Outlook remains positive given the 71% buy rating consensus and $60 price target representing 5% upside. Key risks include energy market volatility and the Q1 2026 earnings miss, but the company's fee-based contracts and Permian Basin exposure provide stability. The sustainable dividend and strong cash flow generation support long-term value for income-focused investors.
Merck (MRK) trades at $126.27, down 0.96% on the day, with a neutral technical signal and strong fundamental performance. The company reported robust 2025 results with $65.01B revenue and $18.25B net income, beating EPS estimates in recent quarters. Recent news highlights Merck's acquisition of Terns Pharmaceuticals to bolster its oncology pipeline, while analyst consensus remains bullish with a $137.30 price target.
Outlook is positive driven by earnings momentum and strategic M&A, but risks include patent expirations and competitive pressures. The stock offers a dividend yield with upcoming payment, supporting income investors. Valuation multiples are elevated, requiring sustained growth to justify current levels amid macroeconomic uncertainties.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About MPLX LP
MPLX LP is a Master Limited Partnership (MLP) formed by Marathon Petroleum Corporation (MPC). It is a diversified, growth-oriented company primarily engaged in the gathering, processing, and transportation of natural gas and natural gas liquids (NGLs), as well as the transportation, storage, and distribution of crude oil and refined petroleum products. MPLX owns and operates a network of midstream energy infrastructure assets, providing essential services to the energy industry across the United States.
Read more on MPLX →About Merck & Co., Inc.
Merck makes pharmaceutical products to treat several conditions in a number of therapeutic areas, including cardiometabolic disease, cancer, and infections. Within cancer, the firm's immuno-oncology platform is growing as a major contributor to overall sales. The company also has a substantial vaccine business, with treatments to prevent hepatitis B and pediatric diseases as well as HPV and shingles. Additionally, Merck sells animal health-related drugs. From a geographical perspective, just under half of the firm's sales are generated in the United States.
Read more on MRK →
